Johnson & Johnson (JNJ) Holdings Raised by Nexus Investment Management Inc.
Nexus Investment Management Inc. raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,460 shares of the company’s stock after purchasing an additional 200 shares during the quarter. Nexus Investment Management Inc.’s holdings in Johnson & Johnson were worth $1,251,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Lenox Wealth Advisors Inc. grew its stake in Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its stake in Johnson & Johnson by 241.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after purchasing an additional 841 shares in the last quarter. Ullmann Financial Group Inc. acquired a new stake in Johnson & Johnson during the 1st quarter valued at approximately $186,000. Taylor Wealth Management Partners grew its stake in Johnson & Johnson by 19.8% during the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after purchasing an additional 250 shares in the last quarter. Finally, Foundation Resource Management Inc. acquired a new stake in Johnson & Johnson during the 1st quarter valued at approximately $204,000. Hedge funds and other institutional investors own 65.90% of the company’s stock.
Shares of Johnson & Johnson (JNJ) traded up 0.02% during mid-day trading on Friday, reaching $133.22. The company’s stock had a trading volume of 2,469,506 shares. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08. The company has a 50 day moving average of $132.23 and a 200-day moving average of $129.87. The firm has a market capitalization of $357.56 billion, a P/E ratio of 22.54 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.79 by $0.04. The business had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. Johnson & Johnson’s revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.74 EPS. Equities research analysts forecast that Johnson & Johnson will post $7.18 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.52%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s payout ratio is currently 56.76%.
A number of research firms have commented on JNJ. Credit Suisse Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Friday, August 4th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $120.00 target price on shares of Johnson & Johnson in a report on Wednesday. Vetr downgraded Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price on the stock. in a report on Monday, September 18th. Alembic Global Advisors downgraded Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Finally, UBS AG reaffirmed a “buy” rating and set a $148.00 target price on shares of Johnson & Johnson in a report on Thursday, August 31st. Five equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Hold” and a consensus target price of $134.79.
In other news, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) Holdings Raised by Nexus Investment Management Inc.” was posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.watchlistnews.com/johnson-johnson-jnj-holdings-raised-by-nexus-investment-management-inc/1618251.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.